Pfizer Inc (NYSE:PFE) said Wednesday that three shots of its vaccine are effective at neutralizing the Omicron variant of COVID-19. The information stems from a laboratory test the pharma giant carried out, while it further announced that an Omicron-specific vaccine could be ready in March 2022. Q3 2021 hedge fund letters, conferences and more 25 Times More AntibodiesAs reported by Reuters, Pfizer —together with BioNTech SE -ARD (NASDAQ:BNTX)—has established that two doses of its Covid vaccine could not offer enough antibodies against the Omicron strain. However, a third shot could boost antib…

Read More